Frank et al. found that NSCLC patients with KEAP1/NRF2 activating mutations do not respond to second/third line chemotherapy [97]; moreover, Ceston et al. found that LUSC patients with NRF2 active do not benefit from adjuvant chemotherapy comparing to the ones with the NRF2 unaltered [140]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.